CompletedPhase 1ACTRN12608000521325

Epstein-Barr Virus (EBV) -specific T cells as therapy for relapsed / refractory EBV-positive lymphomas

Epstein-Barr Virus (EBV)-specific T cells as therapy for relapsed/refractory EBV-positive lymphomas

Sponsor

Queensland Institute of Medical Research (QIMR)

Enrollment

20 participants

Start Date

Oct 23, 2008

Study Type

Interventional

Conditions

Relapsed or refractory EBV-positive lymphoma

Summary

This trial will use a new method of treating lymphoma using a therapy derived from a person’s Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. The cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. Potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study uses specially grown immune cells (EBV-specific T cells) to treat lymphoma that is linked to the Epstein-Barr virus and has not responded to or has come back after previous treatment. Participants must be 18 or older with EBV-positive lymphoma and a life expectancy of at least 6 months. People with HIV or active hepatitis infections cannot participate.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Autologous AdE1-Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes. Dose, duration and mode of administration: total dose 20-800 million CTL given in 4 equal doses (each dose 5-200 million CTL) i

Autologous AdE1-Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes. Dose, duration and mode of administration: total dose 20-800 million CTL given in 4 equal doses (each dose 5-200 million CTL) intravenously, at weekly intervals for the first cohort of 10 patients, and twice a week for the second cohort of ten patients.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000521325